{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:40:06Z","timestamp":1788928806269,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00115-020-00871-7","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T14:05:37Z","timestamp":1582121137000},"page":"294-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neue Therapien der spinalen Muskelatrophie","New treatments for spinal muscular atrophy"],"prefix":"10.1007","volume":"91","author":[{"given":"C. D.","family":"Wurster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"871_CR1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn\u00a0MR, Wang\u00a0CH (2008) Spinal muscular atrophy. Lancet 371:2120\u20132133","journal-title":"Lancet"},{"key":"871_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman\u00a0RI, Wijngaarde\u00a0CA, Stam\u00a0M, Bartels\u00a0B, Otto\u00a0LAM, Lemmink\u00a0HH et al (2018) Muscle strength and motor function throughout life in a\u00a0cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20114. Eur J Neurol 25:512\u2013518","journal-title":"Eur J Neurol"},{"key":"871_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel\u00a0RS, McDermott\u00a0MP, Kaufmann\u00a0P, Darras\u00a0BT, Chung\u00a0WK, Sproule\u00a0DM et\u00a0al (2014) Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83:810\u2013817","journal-title":"Neurology"},{"key":"871_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton\u00a0G, Gillingwater\u00a0TH (2013) Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 19:40\u201350","journal-title":"Trends Mol Med"},{"key":"871_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2019.01098","volume":"10","author":"R G\u00fcnther","year":"2019","unstructured":"G\u00fcnther\u00a0R, Wurster\u00a0CD, Cordts\u00a0I, Koch\u00a0JC, Kamm\u00a0C, Petzold\u00a0D et al (2019) Patient-reported prevalence of non-motor symptoms is low in adult patients suffering from 5q spinal muscular atrophy. Front Neurol 10:1\u20137","journal-title":"Front Neurol"},{"key":"871_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre\u00a0S, B\u00fcrglen\u00a0L, Reboullet\u00a0S, Clermont\u00a0O, Burlet\u00a0P, Viollet\u00a0L et al (1995) Identification and characterization of a\u00a0spinal muscular atrophy-determining gene. Cell 80:155\u2013165","journal-title":"Cell"},{"key":"871_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","volume":"10","author":"AHM Burghes","year":"2009","unstructured":"Burghes\u00a0AHM, Beattie\u00a0CE (2009) Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 10:597\u2013609","journal-title":"Nat Rev Neurosci"},{"key":"871_CR8","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson\u00a0CL, Hahnen\u00a0E, Androphy\u00a0EJ, Wirth\u00a0B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S\u00a0A 96:6307\u20136311","journal-title":"Proc Natl Acad Sci U S A"},{"key":"871_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"RI Wadman","year":"2016","unstructured":"Wadman\u00a0RI, Stam\u00a0M, Gijzen\u00a0M, Lemmink\u00a0HH, Snoeck\u00a0IN, Wijngaarde\u00a0CA et\u00a0al (2016) Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J\u00a0Neurol Neurosurg Psychiatry 88:365\u2013367","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"871_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea\u00a0GE, Kr\u00f6ber\u00a0S, McWhorter\u00a0ML, Rossoll\u00a0W, M\u00fcller\u00a0S, Krawczak\u00a0M et\u00a0al (2008) Plastin 3 is a\u00a0protective modifier of autosomal recessive spinal muscular atrophy. Science 320:524\u2013527","journal-title":"Science"},{"key":"871_CR11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland\u00a0M, Kaczmarek\u00a0A, Schneider\u00a0S, Swoboda\u00a0KJ, L\u00f6hr\u00a0H, Bradler\u00a0C et\u00a0al (2017) Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet 100:297\u2013315","journal-title":"Am J Hum Genet"},{"key":"871_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","volume":"99","author":"S Hosseinibarkooie","year":"2016","unstructured":"Hosseinibarkooie\u00a0S, Peters\u00a0M, Torres-Benito\u00a0L, Rastetter\u00a0RHH, Hupperich\u00a0K, Hoffmann\u00a0A et al (2016) The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet 99:647\u2013665","journal-title":"Am J Hum Genet"},{"key":"871_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-180333","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill\u00a0K, K\u00f6lbel\u00a0H, Schwartz\u00a0O, Blaschek\u00a0A, Olgem\u00f6ller\u00a0B, Harms\u00a0E et\u00a0al (2019) One year of newborn screening for SMA\u2014results of a\u00a0German pilot project. J\u00a0Neuromuscul Dis 6:1\u201313","journal-title":"J Neuromuscul Dis"},{"key":"871_CR14","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini\u00a0MA, Bu\u00a0J, Richards\u00a0AM, Kinnecom\u00a0C, Sardi\u00a0SP, Stanek\u00a0LM et\u00a0al (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3:72ra18","journal-title":"Sci Transl Med"},{"key":"871_CR15","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua\u00a0Y, Sahashi\u00a0K, Hung\u00a0G, Rigo\u00a0F, Passini\u00a0MA, Bennett\u00a0CF et\u00a0al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a\u00a0type III SMA mouse model. Genes Dev 24:1634\u20131644","journal-title":"Genes Dev"},{"key":"871_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel\u00a0RS, Mercuri\u00a0E, Darras\u00a0BT, Connolly\u00a0AM, Kuntz\u00a0NL, Kirschner\u00a0J et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732","journal-title":"N. Engl. J. Med."},{"key":"871_CR17","first-page":"210","volume":"27","author":"E Mercuri","year":"2017","unstructured":"Mercuri\u00a0E, Finkel\u00a0R, Kirschner\u00a0J, Chiriboga\u00a0C, Kuntz\u00a0N, Sun\u00a0P et al (2017) Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study. Neuromuscul Disord 27:210","journal-title":"Neuromuscul Disord"},{"key":"871_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo\u00a0DC, Bertini\u00a0E, Swoboda\u00a0KJ, Hwu\u00a0W\u2011L, Crawford\u00a0TO, Finkel\u00a0RS et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 29:842\u2013856","journal-title":"Neuromuscul Disord"},{"key":"871_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00415-018-9124-0","volume":"266","author":"CD Wurster","year":"2019","unstructured":"Wurster\u00a0CD, Winter\u00a0B, Wollinsky\u00a0K, Ludolph\u00a0AC, Uzelac\u00a0Z, Witzel\u00a0S et\u00a0al (2019) Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. J\u00a0Neurol 266:183\u2013194","journal-title":"J Neurol"},{"key":"871_CR20","volume-title":"Spinraza. Product information","author":"Biogen","year":"2019","unstructured":"Biogen (2019) Spinraza. Product information"},{"key":"871_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2019.01179","volume":"10","author":"CD Wurster","year":"2019","unstructured":"Wurster\u00a0CD, Koch\u00a0JC, Cordts\u00a0I, Dreyhaupt\u00a0J, Otto\u00a0M, Uzelac\u00a0Z et\u00a0al (2019) Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen. Front Neurol 10:1\u201310","journal-title":"Front Neurol"},{"key":"871_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter\u00a0MC, Wenninger\u00a0S, Thiele\u00a0S, Stauber\u00a0J, Hiebeler\u00a0M, Greckl\u00a0E et al (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J\u00a0Neuromuscul Dis 6:453\u2013465","journal-title":"J Neuromuscul Dis"},{"key":"871_CR23","unstructured":"Hagenacker\u00a0T, Wurster\u00a0CD, G\u00fcnther\u00a0R, Schreiber-Katz\u00a0O, Osmanovic\u00a0A, Petri\u00a0S et al (accepted) Nusinersen in Adult Spinal Muscular Atrophy: a non-interventional, multicentre, 14-months observational cohort study. Lancet Neurol"},{"key":"871_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell\u00a0JR, Al-Zaidy\u00a0S, Shell\u00a0R, Arnold\u00a0WD, Rodino-Klapac\u00a0LR, Prior\u00a0TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713\u20131722","journal-title":"N. Engl. J. Med."},{"key":"871_CR25","volume-title":"Zolgensma full prescribing information","author":"Novartis","year":"2019","unstructured":"Novartis (2019) Zolgensma full prescribing information"},{"key":"871_CR26","first-page":"2230","volume":"48","author":"T Maybaum","year":"2019","unstructured":"Maybaum\u00a0T, Gie\u00dfelmann\u00a0K (2019) Kassen und \u00c4rzte unter Druck. Dtsch Arztebl 48:2230","journal-title":"Dtsch Arztebl"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-020-00871-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00871-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T02:36:55Z","timestamp":1613702215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-020-00871-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s00115-020-00871-7","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"19 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.D.\u00a0Wurster hat von der Firma Biogen Honorare als Advisory-Board-Teilnehmer und f\u00fcr Vortr\u00e4ge erhalten; von der Firma Hoffmann-La Roche hat sie Honorare f\u00fcr Beratert\u00e4tigkeiten u.\u202fa. als Advisory-Board-Teilnehmer erhalten. Sie erhielt zudem Unterst\u00fctzung bei Reisekosten von der Firma Biogen. R.\u00a0G\u00fcnther hat von der Firma Biogen und Hoffmann-La Roche Honorare als Advisory-Board-Teilnehmer erhalten sowie eine Forschungsf\u00f6rderung von der Firma Biogen. Er erhielt zudem Unterst\u00fctzung bei Reisekosten von der Firma Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}